Funder
Department of Veterans Affairs
National Institutes of Health
National Cancer Institute
Reference75 articles.
1. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection;Lehmann;PLoS One,2016
2. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes;Lehmann;Nat. Commun.,2021
3. Pembrolizumab Plus Chemotherapy versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): a Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial;Cortes,2020
4. Event-free survival with pembrolizumab in early triple-negative breast cancer;Schmid;N. Engl. J. Med.,2022
5. Pembrolizumab for early triple-negative breast cancer;Schmid;N. Engl. J. Med.,2020